Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: A dose-finding trial in two centres

Malaria Journal

Volumn 14, Issue 1, 2015, Pages

  Mordmüller, Benjamin ^a   Supan, Christian ^a   Sim, Kim Lee ^b   Gómez Pérez, Gloria P ^c   Ospina Salazar, Carmen Lucelly ^a   Held, Jana ^a   Bolte, Stefanie ^a   Esen, Meral ^a   Tschan, Serena ^a   Joanny, Fanny ^a   Lamsfus Calle, Carlos ^a   Löhr, Sascha J Z ^a   Lalremruata, Albert ^a   Gunasekera, Anusha ^b   James, Eric R ^b   Billingsley, Peter F ^b   Richman, Adam ^b   Chakravarty, Sumana ^b   Legarda, Almudena ^c   Muñoz, Jose ^c   Antonijoan, Rosa M ^d,e   Ballester, Maria Rosa ^d,e   Hoffman, Stephen L ^b   Alonso, Pedro L ^c   Kremsner, Peter G ^a   more..

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b SANARIA INC   (United States)

^c CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Clinical trial; Controlled human malaria infection; Malaria; Microbial challenge; Plasmodium falciparum sporozoite

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; CHLOROQUINE; LIVER ENZYME; MALARIA VACCINE; SPOROZOITE VACCINE;

ABNORMAL LABORATORY RESULT; ABNORMAL URINE COMPOSITION; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; BILIRUBINURIA; BLOOD SMEAR; CONTROLLED STUDY; CRYOPRESERVATION; DIRECT VENOUS INOCULATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GEOMETRIC MEAN PRE PATENT PERIOD; GEOMETRY; HUMAN; INDWELLING CATHETER; INFECTION RATE; INOCULATION; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LYMPHOCYTOPENIA; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; MAXIMUM PERMISSIBLE DOSE; MICROORGANISM DETECTION; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PARASITEMIA; PATIENT SAFETY; PLASMODIUM FALCIPARUM; QUANTITATIVE ANALYSIS; RADIATION ATTENUATION; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SPOROZOITE; VACCINATION; VOLUNTEER; ADOLESCENT; CLINICAL TRIAL; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PARASITOLOGY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PARASITEMIA; PLASMODIUM FALCIPARUM; SPOROZOITES; YOUNG ADULT;

EID: 84925386105     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/s12936-015-0628-0     Document Type: Article

References (35)

1. WHO. World Malaria Report 2014. Geneva: World Health Organization; 2014.
2. Mordmüller B, Kremsner PG. Malarial parasites vs. antimalarials: never-ending rumble in the jungle. Curr Mol Med. 2006;6:247-51.
3. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol. 2011;11:57-64.
4. Fairley H. Chemotherapeutic suppression and prophylaxis in malaria. Trans R Soc Trop Med Hyg. 1945;38:311-55.
5. Verhage DF, Telgt DSC, Bousema JT, Hermsen CC, van Gemert GJA, van der Meer JWM, et al. Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J Med. 2005;63:52-8.
6. Rickman LS, Jones TR, Long GW, Paparello S, Schneider I, Paul CF, et al. Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg. 1990;43:441-5.
7. Lyke KE, Laurens M, Adams M, Billingsley PF, Richman A, Loyevsky M, et al. Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS One. 2010;5:e13490.
8. Epstein JE, Rao S, Williams F, Freilich D, Luke T, Sedegah M, et al. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis. 2007;196:145-54.
9. Laurens MB, Billingsley P, Richman A, Eappen AG, Adams M, Li T, et al. Successful human infection with P. falciparum using three aseptic Anopheles stephensi mosquitoes: a new model for controlled human malaria infection. PLoS One. 2013;8:e68969.
10. Roestenberg M, O'Hara GA, Duncan CJA, Epstein JE, Edwards NJ, Scholzen A, et al. Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One. 2012;7:e38434.
11. Hoffman SL, Goh LML, Luke TC, Schneider I, Le TP, Doolan DL, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis. 2002;185:1155-64.
12. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci. 1973;266:169-77.
13. Seder RA, Chang L-J, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359-65.
14. + T cell immunity. Science. 2011;334:475-80.
15. Sheehy SH, Spencer AJ, Douglas AD, Sim BKL, Longley RJ, Edwards NJ, et al. Optimising controlled human malaria infection studies using cryopreserved P. falciparum parasites administered by needle and syringe. PLoS One. 2013;8:e65960.
16. Roestenberg M, Bijker EM, Sim BKL, Billingsley PF, James ER, Bastiaens GJH, et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2013;88:5-13.
17. Shekalaghe S, Rutaihwa M, Billingsley PF, Chemba M, Daubenberger CA, James ER, et al. Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014;91:471-80.
18. Hodgson SH, Juma E, Salim A, Magiri C, Kimani D, Njenga D, et al. Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol. 2014;5:686.
19. Gaziano TA, Young CR, Fitzmaurice G, Atwood S, Gaziano JM. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet. 2008;371:923-31.
20. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin. 2010;6:97-106.
21. Planche T, Krishna S, Kombila M, Engel K, Faucher JF, Ngou-Milama E, et al. Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg. 2001;65:599-602.
22. Hermsen CC, Telgt DS, Linders EH, van de Locht LA, Eling WM, Mensink EJ, et al. Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol. 2001;118:247-51.
23. Haas CN. Estimation of risk due to low doses of microorganisms: a comparison of alternative methodologies. Am J Epidemiol. 1983;118:573-82.
24. Bonhoeffer J, Bentsi-Enchill A, Chen RT, Fisher MC, Gold MS, Hartman K, et al. Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine. 2009;27:2289-97.
25. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2014. [ http://www.R-project.org/ ]
26. Turner L, Wang CW, Lavstsen T, Mwakalinga SB, Sauerwein RW, Hermsen CC, et al. Antibodies against PfEMP1, RIFIN, MSP3 and GLURP are acquired during controlled Plasmodium falciparum malaria infections in naïve volunteers. PLoS One. 2011;6:e29025.
27. Richie TL, Charoenvit Y, Wang R, Epstein JE, Hedstrom RC, Kumar S, et al. Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccines Immunother. 2012;8:1564-84.
28. Vanderberg JP, Frevert U. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol. 2004;34:991-6.
29. Sinnis P, Zavala F. The skin: where malaria infection and the host immune response begin. Semin Immunopathol. 2012;34:787-92.
30. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature. 1967;216:160-2.
31. Choumet V, Attout T, Chartier L, Khun H, Sautereau J, Robbe-Vincent A, et al. Visualizing non infectious and infectious Anopheles gambiae blood feedings in naive and saliva-immunized mice. PLoS One. 2012;7:e50464.
32. Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW. Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum. Trans R Soc Trop Med Hyg. 1974;68:258-9.
33. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJF, van Gemert GJ, et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009;361:468-77.
34. Bijker EM, Bastiaens GJH, Teirlinck AC, van Gemert G-J, Graumans W, van de Vegte-Bolmer M, et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci U S A. 2013;110:7862-7.
35. Safety and protective efficacy of intravenous immunization with cryopreserved Plasmodium falciparum sporozoites under chemoprophylaxis [ http://clinicaltrials.gov/ct2/show/NCT02115516 ]